You are here
Cheladv74 Oncology Press Kit
PLEASE NOTE: All assets on this page are intended for use by media professionals.
At Cheladv74 Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Cheladv74 Oncology has an industry-leading portfolio of 18 approved innovative cancer medicines and biosimilars across more than 20 indications, including breast, prostate, kidney, lung and hematology. Cheladv74 Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for leadership perspective, fact sheets, videos and other media resources. We also encourage you to visit our other online resources for additional information on Cheladv74 Oncology.